C-Path Makes Progress to Safely Speed Medical Discoveries to Market
William Mattes of C-Path spoke at the Arizona Pavillion May 8th 2007 about the Predictive Safety Testing Consortium.
Related Posts
-
C-Path Receives COA Qualification from FDA for the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) -
Critical Path Institute Receives Regulatory Support for Liver Injury Biomarker -
miR-122 An Exploratory Biomarker of Liver Injury: An Industry Perspective on the State of the Science and Experiences Pre-Clinically and Clinically -
Drug-Induced Liver Injury (DILI) Conference XVII -
Safety, Dosing, and Pharmaceutical Quality for Studies That Evaluate Medicinal Products (Including Biological Products) in Neonates